Literature DB >> 26963343

Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.

Mutsuki Kuraoka1, En Kimura2, Tetsuya Nagata3, Takashi Okada4, Yoshitsugu Aoki1, Hisateru Tachimori5, Naohiro Yonemoto6, Michihiro Imamura1, Shin'ichi Takeda7.   

Abstract

Duchenne muscular dystrophy is a lethal X-linked muscle disorder. We have already reported that osteopontin (OPN), an inflammatory cytokine and myogenic factor, is expressed in the early dystrophic phase in canine X-linked muscular dystrophy in Japan, a dystrophic dog model. To further explore the possibility of OPN as a new biomarker for disease activity in Duchenne muscular dystrophy, we monitored serum OPN levels in dystrophic and wild-type dogs at different ages and compared the levels to other serum markers, such as serum creatine kinase, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1. Serum OPN levels in the dystrophic dogs were significantly elevated compared with those in wild-type dogs before and 1 hour after a cesarean section birth and at the age of 3 months. The serum OPN level was significantly correlated with the phenotypic severity of dystrophic dogs at the period corresponding to the onset of muscle weakness, whereas other serum markers including creatine kinase were not. Immunohistologically, OPN was up-regulated in infiltrating macrophages and developmental myosin heavy chain-positive regenerating muscle fibers in the dystrophic dogs, whereas serum OPN was highly elevated. OPN expression was also observed during the synergic muscle regeneration process induced by cardiotoxin injection. In conclusion, OPN is a promising biomarker for muscle regeneration in dystrophic dogs and can be applicable to boys with Duchenne muscular dystrophy.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26963343     DOI: 10.1016/j.ajpath.2016.01.002

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  16 in total

1.  Osteopontin promotes infarct repair.

Authors:  Itai Rotem; Tal Konfino; Tal Caller; Yeshai Schary; Olga Shaihov-Teper; Dahlia Palevski; Nir Lewis; Daria Lendengolts; Nili Naftali-Shani; Jonathan Leor
Journal:  Basic Res Cardiol       Date:  2022-10-14       Impact factor: 12.416

2.  Magnetic field therapy enhances muscle mitochondrial bioenergetics and attenuates systemic ceramide levels following ACL reconstruction: Southeast Asian randomized-controlled pilot trial.

Authors:  Mary C Stephenson; Lingaraj Krishna; Rina Malathi Pannir Selvan; Yee Kit Tai; Craig Jun Kit Wong; Jocelyn Naixin Yin; Shi-Jie Toh; Federico Torta; Alexander Triebl; Jürg Fröhlich; Christian Beyer; Jing Ze Li; Sara S Tan; Chun-Kit Wong; Duraimurugan Chinnasamy; Leroy Sivappiragasam Pakkiri; Chester Lee Drum; Markus R Wenk; John J Totman; Alfredo Franco-Obregón
Journal:  J Orthop Translat       Date:  2022-10-13       Impact factor: 4.889

Review 3.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

4.  Early Inflammation in Muscular Dystrophy Differs between Limb and Respiratory Muscles and Increases with Dystrophic Severity.

Authors:  Zachary M Howard; Jeovanna Lowe; Anton J Blatnik; Deztani Roberts; Arthur H M Burghes; Shyam S Bansal; Jill A Rafael-Fortney
Journal:  Am J Pathol       Date:  2021-01-23       Impact factor: 4.307

5.  Age-Dependent Dysregulation of Muscle Vasculature and Blood Flow Recovery after Hindlimb Ischemia in the mdx Model of Duchenne Muscular Dystrophy.

Authors:  Paulina Podkalicka; Olga Mucha; Katarzyna Kaziród; Iwona Bronisz-Budzyńska; Sophie Ostrowska-Paton; Mateusz Tomczyk; Kalina Andrysiak; Jacek Stępniewski; Józef Dulak; Agnieszka Łoboda
Journal:  Biomedicines       Date:  2021-04-27

6.  Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells.

Authors:  Peter P Nghiem; Joe N Kornegay; Kitipong Uaesoontrachoon; Luca Bello; Ying Yin; Akanchha Kesari; Priya Mittal; Scott J Schatzberg; Gina M Many; Norman H Lee; Eric P Hoffman
Journal:  Muscle Nerve       Date:  2017-08-13       Impact factor: 3.217

Review 7.  "The Social Network" and Muscular Dystrophies: The Lesson Learnt about the Niche Environment as a Target for Therapeutic Strategies.

Authors:  Ornella Cappellari; Paola Mantuano; Annamaria De Luca
Journal:  Cells       Date:  2020-07-09       Impact factor: 6.600

8.  Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs.

Authors:  Mutsuki Kuraoka; Yuko Nitahara-Kasahara; Hisateru Tachimori; Naohiro Kato; Hiroyuki Shibasaki; Akihiko Shin; Yoshitsugu Aoki; En Kimura; Shin'ichi Takeda
Journal:  PLoS One       Date:  2018-12-11       Impact factor: 3.240

Review 9.  Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.

Authors:  Shouta Miyatake; Yuko Shimizu-Motohashi; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Drug Des Devel Ther       Date:  2016-08-30       Impact factor: 4.162

10.  Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.

Authors:  Eike A Strathmann; Miriam Peters; Seyyedmohsen Hosseinibarkooie; Frank W Rigo; C Frank Bennett; Phillip G Zaworski; Karen S Chen; Michael Nothnagel; Brunhilde Wirth
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.